Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 334 results for "Victoza"

Pending EC decision: Victoza, liraglutide, Opinion date: 28-A...

the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Victoza. The marketing authorisation holder for this medicinal product ... European Medicines Agency, 5 days ago

Human medicines European public assessment report (EPAR): Victoza, liraglutide, Revision: 14, Authorised

This is a summary of the European public assessment report (EPAR) for Victoza. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and ...
 European Medicines Agency2 weeks ago NOVO NORDISK A/S : Victoza┬« liraglutide injection Provided Superior HbA1c Reductions in Adults With Type 2 Diabetes Compared to Continued Sitagliptin...  4 Traders2 weeks ago BRIEF-Novo says Victoza reduces glycated haemoglobin more than sitagliptin  Reuters UK1 month ago New data for liraglutide in type 2 diabetes  GM Journal1 month ago

Victoza to Fuel Growth for Novo Nordisk

What Factors Support Novo Nordisk's Premium Valuation? ( Continued from Prior Part ) Victoza is a key product in Novo's portfolio Victoza is a glucagon-like peptide-1 (or GLP-1) class drug from Novo Nordisk (NVO). During fiscal 2015, the drug ...
 Yahoo! Finance UK and Ireland2 weeks ago How Has Novo's Share Price Performed since Its Last Earnings?  Yahoo! Finance UK and Ireland2 days ago Novo Nordisk invests $100m in diabetes pipeline purification plant  BioPharma-Reporter.com1 week ago How Is Novo Nordisk Doing in the Diabetes Space?  Yahoo! Finance UK and Ireland3 weeks ago

Novo Nordisk A/S 1Q 2016 -- Forecast

=== Sales: -NovoRapid/ 1st Quarter -Total -Victoza -Levemir NovoLog AVERAGE 26,975 4,589 4,400 4,998 Prev. Year 25,200 3,957 ...
 Morningstar.com1 week ago Novo Nordisk: Earnings Are In, When Will This Stock Lift Off?  Seeking Alpha2 days ago Novo Nordisk cuts annual guidance due to currency effects  FirstWord Pharma5 days ago NOVO NORDISK A/S : Trims Guidance on Currency Rates  4 Traders6 days ago

Now Novo Says Semaglutide Cuts CV Risk: SUSTAIN-6 Top-line Data

Just over a month after Novo Nordisk announced positive top-line results for liraglutide (Victoza, Novo Nordisk), showing that it significantly reduced the risk of major adverse cardiovascular events in the LEADER Liraglutide Effect and Action in ...
 RxList5 days ago Novo Nordisk Receives Positive CHMP Opinion for Extended Victoza Indication  FirstWord Pharma5 days ago New and Generic Drug Approvals: Victoza  U.S. Food and Drug Administration1 week ago Novo says Victoza bests MSD's Januvia at lowering blood sugar  Pharmafile1 month ago
SRN News

Novo Nordisk and AstraZeneca seek tonic from key drug trials

* Data due on cardiovascular profile of Novo's Victoza * AstraZeneca aims to show Brilinta benefits in strokeBy Ben Hirschler LONDON, March 1 (Reuters) - Novo Nordisk and AstraZeneca, two drugmakers whose financial outlooks disappointed investors ...
 London South East2 months ago
European Pharmaceutical Review

New data for semaglutide and liraglutide presented at ENDO 2016

Novo Nordisk has presented new data for semaglutide and Victoza (liraglutide) at the Endocrine Society's 98th Annual Meeting and Expo (ENDO 2016) in Boston, MA, US. Findings from the first Phase IIIa clinical trial for semaglutide, demonstrated ...
 European Pharmaceutical Review1 month ago
Monthly Prescribing Reference

Drug Switch Leads to Superior HbA1c Reduction in Sitagliptin vs. Victoza Study

Share this article: Victoza is a glucagon-like peptide-1 (GLP-1) receptor agonist Switching from sitagliptin to Victoza (liraglutide [rDNA origin]; Novo Nordisk), in combination with metformin, showed superior HbA1c reductions vs. continuing ...
 Monthly Prescribing Reference1 month ago

Diabetes Injection Pens Market 2016-2020 Industry Examined by Syndicate Market Research

Diabetes Injection Pens Market 2016 Industry Share , Growth , Size and Forecast to 2020 This press release was orginally distributed by SBWire Deerfield Beach, FL -- (SBWIRE) -- 05/04/2016 -- Diabetes is a metabolic disease that hampers the ...
 Digital Journal18 hours ago Nonalcoholic Steatohepatitis Market 2016-2020 Industry exmined by Syndicate Market Research  BioSpace1 week ago Antidiabetics Market 2016-2020 Industry exmined by Syndicate Market Research  Minyanville1 week ago Global Nonalcoholic Steatohepatitis Market 2016 Industry Analysis SegmentForecast up to 2014 2020  MENAFN3 weeks ago
American Banking News - Forex

Analysts Upgrades for May, 3rd (ACOR, CPHD, CRAI, CTB, DCI, DRE, FSTR, HTGC, HWAY, IM)

Analysts upgrades for Tuesday, May 3rd: Acorda Therapeutics (NASDAQ:ACOR) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. Zacks Investment Research currently has $30.00 target price on the stock. According ...
 American Banking News - Forex1 day ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - Victoza
Get updated on latest news & your favorite topics right in your inbox!
More     Less